NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

BSX

105.3

+0.4%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

BSX

105.3

+0.4%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

BSX

105.3

+0.4%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

BSX

105.3

+0.4%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

BSX

105.3

+0.4%↑

Search

Johnson and Johnson

Chiusa

SettoreSettore sanitario

167.25 1.51

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

164.78

Massimo

167.58

Metriche Chiave

By Trading Economics

Entrata

-5.5B

5.5B

Vendite

1.9B

24B

P/E

Media del settore

17.797

40.048

EPS

2.77

Rendimento da dividendi

2.98

Margine di Profitto

23.321

Dipendenti

138,100

EBITDA

-9.1B

6.5B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+6.76% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

2.98%

2.45%

Utili prossimi

14 ott 2025

Prossima data del Dividendo

9 set 2025

Prossima data del' Ex Dividendo

26 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

23B

400B

Apertura precedente

165.74

Chiusura precedente

167.25

Notizie sul Sentiment di mercato

By Acuity

36%

64%

98 / 375 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Johnson and Johnson Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 lug 2025, 16:47 UTC

Utili

J&J Raises Full-Year Outlook After Beating 2Q Expectations -- Update

16 lug 2025, 18:08 UTC

Discorsi di Mercato
Utili

J&J's Orthopedic Decline Likely Hinges on Company-Specific Challenges -- Market Talk

16 lug 2025, 17:27 UTC

Discorsi di Mercato
Utili

J&J Expects Medical Devices Sales Boost from Cardiovascular -- Market Talk

16 lug 2025, 17:17 UTC

Discorsi di Mercato
Utili

J&J Sees Growth Across Portfolio Offsetting Loss of Stelara -- Market Talk

16 lug 2025, 16:34 UTC

Discorsi di Mercato
Utili

J&J Sees Lower Tariff Risk for the Year -- Market Talk

16 lug 2025, 13:27 UTC

Utili

Johnson & Johnson Beats Earnings Estimates. CFO Says It Can Do Any Deal It Wants. -- Barrons.com

16 lug 2025, 10:32 UTC

Utili

Johnson & Johnson Beats Earnings Estimates. Financial Chief Says It Can Do Any Deal It Wants. -- Barrons.com

16 lug 2025, 10:22 UTC

Utili

Correct: Johnson & Johnson 2Q International Sales $10.2B >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson Beats Earnings Estimates. Financial Chief Says It Can Do Any Deal It Wants. -- Barrons.com

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson Now Sees 2025 Adjusted Operational EPS $10.63-$10.73 Vs Prior Outlook $10.50-$10.70 >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson Raises 2025 View To Sales $93.2B-$93.6B Vs Prior Outlook $91B-$91.8B >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson Raises 2025 View To Adj EPS $10.80-Adj EPS $10.90 Vs Prior Outlook $10.50-$10.70 >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson: Increasing 2025 Operational Sales Growth to Be in Range of 4.5%-5% Vs Prior Range 3.3%-4.3% >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson Now Sees 2025 Operational Sales of $92.7B-$93.1B Vs Prior Outlook $91.6B-$92.4B>JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson: Our Portfolio and Pipeline Position Us for Elevated Growth in Second Half of Year >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson Now Sees 2025 Adjusted Operational Sales Growth of 3.2%-3.7% Vs Prior Outlook 2%-3% >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson: 2Q MedTech Business Delivered Operational Sales Growth of 6.1%, Driven Primarily by Strength in Electrophysiology Products and Abiomed, Wound Closure Pdts and Improved Performance in Surgical Vision >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson 2Q Worldwide MedTech Sales $8.54B >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson: 2Q Innovative Medicine Operational Sales Growth Driven by Darzalex, Carvykti, Rybrevant, Lazcluze, Tremfya and Spravato >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson: 2Q Innovative Medicine Operational Sales Grew 3.8% With 13 Brands Growing Double Digits >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson 2Q International Sales $23.74B >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson 2Q Worldwide Innovative Medicine Sales $15.2B >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson 2Q U.S. Sales $13.54B >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson 2Q Sales $23.74B >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson 2Q EPS $2.29 >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson 2Q Adj EPS $2.77 >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson 2Q Orthopaedics Sales $2.3B >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson 2Q Orthopaedics Sales $2.31B >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson 2Q International Sales $10.2B >JNJ

16 lug 2025, 10:20 UTC

Utili

Johnson & Johnson 2Q Worldwide Innovative Medicine Sales $15.2B >JNJ

Confronto tra pari

Modifica del prezzo

Johnson and Johnson Previsione

Obiettivo di Prezzo

By TipRanks

6.76% in crescita

Previsioni per 12 mesi

Media 175.88 USD  6.76%

Alto 190 USD

Basso 160 USD

Basato su 18 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Johnson and Johnson - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

18 ratings

8

Acquista

10

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

154.93 / 155.895Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

98 / 375 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.